People on steroids for chronic illness may be more at risk of COVID-19
An editorial of The Journal of Clinical Endocrinology & Metabolism (JCEM) has suggested that people who take the class of steroid hormones known as glucocorticoids may be more likely to contract COVID-19 and, if they do, are more likely to have severe symptoms. Glucocorticoids are frequently a medication doctors prescribe for chronic inflammatory diseases, such as asthma, chronic obstructive pulmonary disease, and inflammatory bowel disease.
As the novel SARS-CoV-2 virus rapidly spreads across the world, research continues apace to help understand how the virus spreads and what effects it has on people who then develop the disease COVID-19.
Drawing on this emergent research, the editors of the JCEM highlight the possible relationship between the corticosteroids glucocorticoids and COVID-19.
Doctors widely prescribe glucocorticoids for various chronic inflammatory diseases, and they can be highly effective in the treatment of these illnesses. The reason for this is that they significantly reduce inflammation. A further association with this, however, is their suppression of a person’s immune system.
According to the editors of the JCEM, this means people who regularly take glucocorticoids may be more likely to experience an infection with the SARS-CoV-2 virus since their immune systems are likely to be less effective at fighting it off.
This may also mean that a person taking glucocorticoids will experience a more severe case of COVID-19 from infection with the virus.
The World Health Organisation (WHO) currently recommend against the use of glucocorticoids to treat COVID-19.
2026-09-02
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Pfizer's paxlovid reduces the risk of COVID-19 by 26%
-
The battle between Pfizer and Gilead over COVID-19 drugs will continue
-
1200 cases were newly prescribed by Junshi Biologic for mild to moderate disease
-
Twenty-five COVID-19 Vaccines In China Enter Stages Of Clinical Trials
-
Pfizer to Increase Production Capacity of COVID-19 Oral Drugs, Invest 120 Million US Dollars
-
Anke Bio and Afana Collaborate on mRNA Vaccines for Mutant Strains Such as COVID-19 Omicron
-
As Low as $25/session! Pfizer's COVID-19 Oral Drug Paxlovid Generic Drug Price Released
-
Survey On Corona Deaths By Country
-
COVID-19 Drug Remdesivir Approved for Infants And Young Children
-
Roche's Q1 Performance Increases by 10%, And Total Revenue for the Year May Slow Down Due to COVID-19, Biosimilar Competition
Recommend Reading
-
Wacker Under Global Cost Pressure: Dual-Track Restructuring Through Layoffs, Consolidation, and Strategic Repositioning
-
“Clearing the Floor”: DKSH’s Privatization of Its Malaysian Subsidiary Signals a Silent Power Shift in Asia’s Supply Chain
-
European Chemical Firms Face Pressure on First-Quarter Earnings as the War Shock Continues to Spread
-
France’s Wheat Rebounds—But Only Briefly Against a Tsunami of Cheap Grain
-
Congo Copper and Cobalt Miners Are Being Forced to Cut Chemical Use as Middle East Conflict Hits the New Energy Supply Chain
-
Business Society’s Market Outlook for Caustic Soda on August 26, 2026: Volatile Consolidation
-
Bearish Factors Suppress August Hydrogen Peroxide Prices in China
-
Ascorbyl Palmitate: Properties, Uses, and Benefits
-
Business Society’s Market Outlook for MIBK on August 26, 2026: Narrow-Ranging Upward Trend
-
Moving Averages Begin to Entangle, Acrylic Acid Prices Start to Loosen